Ketorolac Trometamol Rompharm (Ketorolac Trometamol)

The active ingredient, ketorolac trometamol, reversibly blocks cyclooxygenase‑1 and cyclooxygenase‑2 enzymes in the eye. This inhibition lowers prostaglandin synthesis, which in turn reduces inflammation, vascular permeability, and pain signaling at the site of application.

The dosage and frequency are determined by the prescribing ophthalmologist based on the specific surgical procedure and patient response. Typically, the medication is administered as one drop to the affected eye(s) as directed by the healthcare professional.

Safety data for ketorolac trometamol in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision should be made by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Ketorolac trometamol is a potent NSAID with a rapid onset of action, often preferred for short‑term postoperative use. Compared with alternatives such as diclofenac eye drops, ketorolac generally provides stronger analgesia but shares a similar safety profile, requiring comparable monitoring for ocular irritation and intra‑ocular pressure changes.

Store the ophthalmic solution at room temperature, below 25 °C, in its original container. Keep the bottle tightly closed, protect it from light and moisture, and discard any product that appears discolored or has been opened beyond the recommended period.

The medication is applied topically as an eye drop. The prescribed number of drops is placed into the conjunctival sac of the affected eye(s) using the provided dropper, typically without touching the tip to the ocular surface to maintain sterility.

Serious adverse events, although rare, include corneal ulceration, severe allergic reactions such as anaphylaxis, Stevens‑Johnson syndrome, significant increases in intra‑ocular pressure, and vision loss. Patients should be instructed to seek immediate medical attention if they experience worsening eye pain, persistent redness, or visual changes.

Ketorolac Trometamol is contraindicated in individuals with known hypersensitivity to ketorolac, other NSAIDs, or any component of the formulation. It should also be avoided in patients with active ocular infections, severe corneal disease, or those using multiple topical NSAIDs simultaneously.